Are Cancer Patients in England Surviving?

Cancer is the leading cause of death in people under 75 in England. Around 390,000 new cases are diagnosed every year, and approximately 167,000 people die from the disease annually. Five-year survival — the standard international measure of cancer system performance — has improved steadily from 46% in 2005 to around 55% in 2023. That trajectory is real and reflects genuine advances in treatment, earlier detection for some cancers, and investment in specialist oncology services. But England still lags behind comparable European countries, and the survival gap is not closing.

The primary driver of England’s relative underperformance is stage at diagnosis. Twenty-six per cent of cancers are diagnosed at stage 4, when the disease has already spread. For many common cancers — lung, bowel, ovarian — the difference in five-year survival between stage 1 and stage 4 diagnosis is the difference between 80–90% survival and 5–15%. COVID disrupted the diagnostic pipeline severely: 40,000 fewer cancers were diagnosed in 2020 than expected. Many of those missing diagnoses eventually presented at later stages, producing a measurable dip in survival statistics that will persist for several years.

The NHS Long-Term Plan set a target of 75% of cancers diagnosed at stage 1 or 2 by 2028. Current performance sits at around 43%. The gap between ambition and reality reflects workforce shortages in radiology and pathology, endoscopy capacity constraints, and the slow rollout of community diagnostic centres. The Faster Diagnosis Standard — 28 days from urgent referral to diagnosis or exclusion — was met for 71% of patients in 2024, meaning nearly three in ten patients waited longer than a month for a diagnosis after their GP flagged concern.

Survival varies significantly by cancer type and by geography. Breast cancer five-year survival exceeds 85%; pancreatic cancer survival remains below 8%. Patients in the most deprived areas of England have consistently lower survival than those in the least deprived areas, a gap that has not narrowed over two decades. Part of this is late presentation, part is comorbidity, and part is differential access to treatment. The National Cancer Audit shows persistent variation in treatment rates between NHS trusts that cannot be explained by case mix alone.

International comparisons should be read carefully. Registry completeness, stage-coding practices, and lead-time bias all affect headline figures. But the consistent finding across CONCORD-3, Eurocare-6, and ICBP studies — that England underperforms northern European peers on survival for the most common cancers — is robust and persistent. The gap is largest for cancers where early detection makes the biggest difference: lung, bowel, and ovarian. This is a system that treats cancer well once it is found, but finds it too late too often.